NTBLQ — Notable Labs Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$3.79m
- $0.31m
Brief: VBL Therapeutics Says Data Safety Committee Gives Clearance To Continue Phase 3 Study Of Ovarian Cancer Treatment
VBL Therapeutics rises on resuming patient enrollment in cancer drug trial
Brief: Vbl Therapeutics Resumes U.S. Enrollment In Oval Phase 3 Trial As FDA Authorizes Clinical Use Of Vb-111 Batches Produced In Modiin Facility
Vascular Biogenics Ltd reports results for the quarter ended in June - Earnings Summary
Brief: Vascular Biogenics Posts Q2 Revenue Of $188,000
Brief: VBL Therapeutics Appoints Marc Kozin As Chairman Of Board
Brief: Vbl Therapeutics Appoints Alison Finger And Michael Rice To Its Board Of Directors
VBL Therapeutics falls on patient recruitment pause in ovarian cancer study
Brief: VBL Therapeutics Provides Update On Phase 3 Study Of VB-111 In Ovarian Cancer
VBL Therapeutics: Jumps on plan to hasten ovarian cancer drug development
Brief: VBL Therapeutics To Provide An Update On The Oval Phase 3 Registration Enabling Study Of Vb-111 In Ovarian Cancer At The 2021 ASCO
Vascular Biogenics Ltd reports results for the quarter ended in March - Earnings Summary
Brief: VBL Therapeutics Reports Q1 Revenue Of $185,000
Vascular Biogenics Ltd expected to post a loss of 13 cents a share - Earnings Preview
VBL Therapeutics: Falls on discounted stock offering
Brief: Vascular Biogenics Ltd Prices Public Offering Of Ordinary Shares And Pre-Funded Warrants
Brief: Vascular Biogenics Announces Proposed Public Offering Of Ordinary Shares And Pre-Funded Warrants
Brief: Vbl Therapeutics Provides Corporate Update
Brief: VBL Therapeutics Announces Peer-Reviewed Publication Of Positive Results Of Pre-Specified Interim Analysis Of Oval, A Phase 3 Registration Enabling Study Of Vb-111 In Ovarian Cancer